Heidelberg, Germany

Stefan Heinig

This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Ascendis Pharma Growth Disorders A/s. Active years: 2025.

USPTO Granted Patents = 1 

% Patents Active = 100.0

Average Co-Inventor Count = 4.0

ph-index = 1


Company Filing History:


Years Active: 2025

Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovations of Stefan Heinig

Introduction

Stefan Heinig is a notable inventor based in Heidelberg, Germany. He has made significant contributions to the field of pharmaceuticals, particularly with his innovative approaches to drug formulations. His work focuses on enhancing the efficacy and stability of pharmaceutical products.

Latest Patents

Stefan Heinig holds a patent for "Dry pharmaceutical formulations of CNP conjugates." This patent describes a dry pharmaceutical formulation that includes a CNP conjugate, a buffering agent, and a bulking agent. The CNP conjugate is characterized by a CNP moiety that is covalently and reversibly conjugated to a polymeric moiety. This innovation aims to improve the delivery and effectiveness of pharmaceutical treatments.

Career Highlights

Heinig is currently associated with Ascendis Pharma Growth Disorders A/S, where he continues to develop groundbreaking pharmaceutical solutions. His expertise in the field has positioned him as a valuable asset to the company and the industry at large.

Collaborations

Stefan Heinig collaborates with esteemed colleagues, including Anja R H Skands and Ulrich Hersel. Their combined efforts contribute to advancing research and development in pharmaceutical formulations.

Conclusion

Stefan Heinig's work exemplifies the spirit of innovation in the pharmaceutical industry. His contributions, particularly in the area of dry pharmaceutical formulations, highlight the importance of research and collaboration in developing effective medical solutions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…